Tuva Health vs Incyte
Side-by-side comparison of AI visibility scores, market position, and capabilities
NY open-source healthcare claims data transformation platform serving 1,500+ practitioners at Oscar Health and MultiCare; YC W22 $6M Virtue-backed first health system-backed open-source data platform competing with Datavant for healthcare analytics engineering.
About
Tuva Health is a New York-based open-source healthcare data transformation company — backed by Y Combinator (W22) with $6 million raised including a $5 million seed round in December 2024 led by Virtue with Box Group, YC, and health technology angels, plus MultiCare Capital Partners (investment from MultiCare Health System making Tuva the first open-source data platform backed by a health system) in February 2025 — operating the Tuva Project, the world's first open-source healthcare data transformation platform that enables payers, providers, and pharmaceutical companies to convert raw claims and EHR datasets into analytics-ready data models through built-in normalization, quality testing, and clinical enrichment. Tuva serves 1,500+ healthcare data practitioners and 30+ partners including Oscar Health and MultiCare.
Wilmington DE oncology/inflammation biopharma (NASDAQ: INCY) ~$3.9B FY2024 revenue; Jakafi $2.7B myelofibrosis franchise, Opzelura topical JAK inhibitor, Novartis Jakavi royalties competing with BMS and Pfizer.
About
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company — publicly traded on the NASDAQ (NASDAQ: INCY) as an S&P 500 Health Care component — focused on oncology and inflammation, best known for Jakafi (ruxolitinib), the first FDA-approved therapy for myelofibrosis and polycythemia vera — rare blood cancers driven by JAK kinase pathway mutations — and the topical ruxolitinib cream Opzelura (for atopic dermatitis and vitiligo). In fiscal year 2024, Incyte reported revenues of approximately $3.9 billion, with Jakafi net product revenues of approximately $2.7 billion (the primary revenue driver) and collaboration revenues from Novartis (which pays Incyte royalties on Jakavi — the ex-US brand name for ruxolitinib — representing a significant royalty income stream from international myelofibrosis and polycythemia vera markets). CEO Hervé Hoppenot's strategy of building a diversified hematology-oncology pipeline beyond ruxolitinib has progressed through the development of axatilimab (anti-CSF-1R monoclonal antibody for chronic graft-versus-host disease — FDA-approved 2024 as Niktimvo) and povorcitinib (JAK inhibitor for prurigo nodularis and hidradenitis suppurativa — phase 3 trials in dermatology). Incyte's JAK inhibitor chemistry platform (ruxolitinib — Jakafi/Opzelura/Jakavi, parsaclisib, itacitinib, tofacitinib licensed from Pfizer collaboration) provides a productive medicinal chemistry foundation for developing next-generation kinase inhibitors with more selective pharmacology profiles.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.